- Home
- CLLS vs XGN Comparison
CLLS vs XGN Comparison
Compare CLLS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- XGN
- Stock Information
- Founded
- CLLS 1999
- XGN 2002
- Country
- CLLS France
- XGN United States
- Employees
- CLLS N/A
- XGN N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- XGN Medical Specialities
- Sector
- CLLS Health Care
- XGN Health Care
- Exchange
- CLLS Nasdaq
- XGN Nasdaq
- Market Cap
- CLLS 143.4M
- XGN 138.3M
- IPO Year
- CLLS 2007
- XGN 2019
- Fundamental
- Price
- CLLS $1.59
- XGN $6.98
- Analyst Decision
- CLLS Buy
- XGN Strong Buy
- Analyst Count
- CLLS 1
- XGN 2
- Target Price
- CLLS $4.00
- XGN $7.50
- AVG Volume (30 Days)
- CLLS 48.2K
- XGN 248.8K
- Earning Date
- CLLS 08-05-2025
- XGN 08-04-2025
- Dividend Yield
- CLLS N/A
- XGN N/A
- EPS Growth
- CLLS N/A
- XGN N/A
- EPS
- CLLS N/A
- XGN N/A
- Revenue
- CLLS $54,747,000.00
- XGN $56,724,000.00
- Revenue This Year
- CLLS $48.52
- XGN $18.92
- Revenue Next Year
- CLLS $5.17
- XGN $14.78
- P/E Ratio
- CLLS N/A
- XGN N/A
- Revenue Growth
- CLLS 351.26
- XGN 1.78
- 52 Week Low
- CLLS $1.10
- XGN $1.78
- 52 Week High
- CLLS $2.43
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- CLLS 56.98
- XGN 52.18
- Support Level
- CLLS $1.56
- XGN $6.82
- Resistance Level
- CLLS $1.49
- XGN $7.15
- Average True Range (ATR)
- CLLS 0.09
- XGN 0.36
- MACD
- CLLS 0.01
- XGN -0.06
- Stochastic Oscillator
- CLLS 80.00
- XGN 37.07
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.